Navigation Links
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
Date:5/15/2009

WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29, 2009 - June 2, 2009 in Orlando, FL.

The results are to be presented in an abstract (number 6018) entitled, "Phase I/II dose escalation study of OncoVEX GM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN)," at a poster session on Friday, May 29, 2009 from 2:00pm - 6:00pm EDT on Level 2, West Hall F3 of the conference. A poster discussion will take place from 5:00pm - 6:00pm EDT.

Study Rationale

Patients with head and neck cancer often present with bulky disease that is too large or too close to vital organs for surgical removal. These patients typically undergo radiation and chemotherapy treatment prior to surgery. Patients who present with tumor containing lymph nodes are particularly difficult to treat and approximately half of these patients relapse within two years.

In this study, OncoVEX GM-CSF was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 Stage III/IVA (N1-3) patients treated, 16 had N2 or N3 disease.

Study Results

The abstract, now available online at www.asco.org, reports that OncoVEX GM-CSF was well tolerated, with no significant additional side effects noted over and above those which are common with chemoradiation alone.
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... VWR (NASDAQ: VWR ), a leading, independent ... of its global website, www.vwr.com , to improve functionality ... site, guests will enjoy enhanced content on a modern and ... site now includes: , a simplified navigation; ... , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... Second Quarter 2015 Investor Conference Call and webcast at 4:30 ... The call will cover an update on Merrimack,s progress ... financials. A press release detailing the information to be ... of Monday, August 10. Investors and the general public ...
Breaking Medicine Technology:ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... , ST. LOUIS , Feb. 1 ... The TODAY Show featured Dr. Mauricio Arruda ... Heart & Vascular Institute in Cleveland, Ohio , performing ... its broadcast this morning.  The patient was a 69 year ...
... DIEGO , Feb. 1 CareFusion (NYSE: ... today that it has entered into a 5-year sole source ... top ten Catholic health systems in the U.S., to upgrade ... further into the operating rooms and cath labs. , CareFusion,s ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 3CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 4
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... the development of it’s new program “Designing Secure Healthcare Systems” This three-day, ... and technology leaders from healthcare organizations with access to the tactics, techniques and ...
(Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... WASHINGTON, Oct. 8 The U.S. Department of,Labor ... 700,jobless workers with partial premium payments for health ... nearly 700 North Carolinians who are,looking for work ... afford health insurance for themselves and their families," ...
... YORK, Oct. 8 Weight Watchers,International, Inc. (NYSE: ... Steven,C. McCormick to serve as its President, North ... with extensive consumer product,operations and general management experience, ... its North American products,publishing and licensing businesses and ...
... their levels correlate with cardiovascular trouble , , WEDNESDAY, Oct. ... activity of genes in white blood cells might someday ... of chest pain, researchers report. , The finding is ... the first issue of a new American Heart Association ...
... Sinobiomed Inc.,("Sinobiomed", or "the Company") (OTC Bulletin ... of Directors voted on October 2, 2008 to ... Officer under a,Corporate Consulting Services Agreement to be ... Choong has been appointed to the Company,s audit,committee. ...
... (OTC Bulletin Board:,VYTC) today announced that effective October ... as an independent scientific consultant to Vyta Corp.,Dr. ... Development at,BIOAGRA, LLC, a joint venture, equally owned ... 15, 2008, Vyta Corp announced its filing of,foreclosure ...
... 8 Dr. Jane Hightower -- widely,acknowledged as the ... who regularly consume certain types of fish -- today,released ... inform and protect,the public from the risks of mercury ... Hightower has released a new book, Diagnosis:,Mercury: Money, Politics, ...
Cached Medicine News:Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Blood Cell Genes May Signal Heart Disease 2Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
Inquire...
Richardson Retractor...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
... implant is an expanded porous polytetrafluoroethylene,material ... repair of the soft tissues of ... in sheets and shaped geometries with ... implant strands are packaged with and,without ...
Medicine Products: